These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

421 related items for PubMed ID: 24863325

  • 1. Health economic impact of high-dose versus standard-dose cytarabine induction chemotherapy for acute myeloid leukaemia.
    Fedele PL, Avery S, Patil S, Spencer A, Haas M, Wei A.
    Intern Med J; 2014 Aug; 44(8):757-63. PubMed ID: 24863325
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.
    Willemze R, Suciu S, Meloni G, Labar B, Marie JP, Halkes CJ, Muus P, Mistrik M, Amadori S, Specchia G, Fabbiano F, Nobile F, Sborgia M, Camera A, Selleslag DL, Lefrère F, Magro D, Sica S, Cantore N, Beksac M, Berneman Z, Thomas X, Melillo L, Guimaraes JE, Leoni P, Luppi M, Mitra ME, Bron D, Fillet G, Marijt EW, Venditti A, Hagemeijer A, Mancini M, Jansen J, Cilloni D, Meert L, Fazi P, Vignetti M, Trisolini SM, Mandelli F, de Witte T.
    J Clin Oncol; 2014 Jan 20; 32(3):219-28. PubMed ID: 24297940
    [Abstract] [Full Text] [Related]

  • 6. Outcome assessment of age group-specific (+/- 50 years) post-remission consolidation with high-dose cytarabine or bone marrow autograft for adult acute myelogenous leukemia.
    Bassan R, Raimondi R, Lerede T, D'emilio A, Buelli M, Borleri G, Personeni A, Bellavita P, Rodeghiero F, Barbui T.
    Haematologica; 1998 Jul 20; 83(7):627-35. PubMed ID: 9718868
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of consolidation therapy with intermediate and high dose cytarabine in acute myeloid leukemia patients.
    Tangchitpianvit K, Rattarittamrong E, Chai-Adisaksopha C, Piriyakhuntorn P, Rattanathammethee T, Hantrakool S, Tantiworawit A, Norasetthada L.
    Hematology; 2021 Dec 20; 26(1):355-364. PubMed ID: 33853503
    [Abstract] [Full Text] [Related]

  • 10. Resource Utilization and Safety of Outpatient Management Following Intensive Induction or Salvage Chemotherapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome: A Nonrandomized Clinical Comparative Analysis.
    Vaughn JE, Othus M, Powell MA, Gardner KM, Rizzuto DL, Hendrie PC, Becker PS, Pottinger PS, Estey EH, Walter RB.
    JAMA Oncol; 2015 Nov 20; 1(8):1120-7. PubMed ID: 26355382
    [Abstract] [Full Text] [Related]

  • 11. Prospective randomization of post-remission therapy comparing autologous peripheral blood stem cell transplantation versus high-dose cytarabine consolidation for acute myelogenous leukemia in first remission.
    Miyamoto T, Nagafuji K, Fujisaki T, Uchida N, Matsue K, Henzan H, Ogawa R, Takase K, Aoki T, Hidaka M, Teshima T, Taniguchi S, Akashi K, Harada M, Japan Study Group for Cell Therapy and Transplantation (JSCT).
    Int J Hematol; 2018 Apr 20; 107(4):468-477. PubMed ID: 29243031
    [Abstract] [Full Text] [Related]

  • 12. High risk of relapse with intermediate dose cytarabine for consolidation in young favourable-risk acute myeloid leukaemia patients following induction with 7+3: a retrospective multicentre analysis and critical review of the literature.
    Kolla BC, Halim NAA, Cao Q, Sachs Z, Warlick E, Weisdorf D, Ho AYL, Chuan WG, Lao Z, He F.
    Br J Haematol; 2021 Jul 20; 194(1):140-144. PubMed ID: 33843048
    [Abstract] [Full Text] [Related]

  • 13. More efficient mobilisation of peripheral blood stem cells with HiDAC+AMSA+G-CSF than with mini-ICE+G-CSF in patients with AML.
    Höglund M, Brune M, Sallerfors B, Ahlgren T, Billström R, Hedenus M, Markevärn B, Nilsson B, Simonsson B, Stockelberg D, Wahlin A.
    Bone Marrow Transplant; 2003 Dec 20; 32(12):1119-24. PubMed ID: 14647265
    [Abstract] [Full Text] [Related]

  • 14. One versus two high-dose cytarabine-based consolidation before autologous stem cell transplantation for young acute myeloblastic leukaemia patients in first complete remission.
    Jourdan E, Rigal-Huguet F, Marit G, Vey N, Dastugue N, Fegueux N, Molina L, Gastaut JA, Legros L, Zerazhi H, Cailleres S, Bauduer F, Bordessoule D, Attal M, Blaise D, Pigneux A, BGMT Study Group.
    Br J Haematol; 2005 May 20; 129(3):403-10. PubMed ID: 15842665
    [Abstract] [Full Text] [Related]

  • 15. Comparison of Three Doses of Cytarabine Consolidation for Intermediate- and Adverse-risk Acute Myeloid Leukemia: Real World Evidence From Thai Acute Myeloid Leukemia Registry.
    Chanswangphuwana C, Polprasert C, Owattanapanich W, Kungwankiattichai S, Rattarittamrong E, Rattanathammethee T, Limvorapitak W, Saengboon S, Niparuck P, Puavilai T, Julamanee J, Saelue P, Wanitpongpun C, Nakhakes C, Prayongratana K, Sriswasdi C.
    Clin Lymphoma Myeloma Leuk; 2022 Oct 20; 22(10):e915-e921. PubMed ID: 35792033
    [Abstract] [Full Text] [Related]

  • 16. Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry.
    Hanoun M, Ruhnke L, Kramer M, Hanoun C, Schäfer-Eckart K, Steffen B, Sauer T, Krause SW, Schliemann C, Mikesch JH, Kaufmann M, Hänel M, Jost E, Brümmendorf TH, Fransecky L, Kraus S, Einsele H, Niemann D, Neubauer A, Kullmer J, Seggewiss-Bernhard R, Görner M, Held G, Kaiser U, Scholl S, Hochhaus A, Reinhardt HC, Platzbecker U, Baldus CD, Müller-Tidow C, Bornhäuser M, Serve H, Röllig C, Study Alliance Leukemia (SAL).
    J Cancer Res Clin Oncol; 2023 Jul 20; 149(8):4611-4621. PubMed ID: 36167894
    [Abstract] [Full Text] [Related]

  • 17. High-dose cytarabine, idarubicin, and granulocyte colony-stimulating factor remission induction therapy for previously untreated de novo and secondary adult acute myeloid leukemia.
    Baer MR, Christiansen NP, Frankel SR, Brunetto VL, Mrózek K, Bloomfield CD, Herzig GP.
    Semin Oncol; 1993 Dec 20; 20(6 Suppl 8):6-12. PubMed ID: 7507264
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Effect of postremission high dose cytarabine-based consolidation chemotherapy before allogenic stem cell transplantation in outcomes of acute myeloid leukemia patients.
    Ciftciler R, Demiroglu H, Buyukasık Y, Okay M, Aksu S, Sayınalp N, Malkan UY, Haznedaroglu IC, Ozcebe O, Goker H.
    Transfus Apher Sci; 2018 Dec 20; 57(6):752-755. PubMed ID: 30249531
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.